MMMostafa El Mansari

Mostafa El Mansari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mostafa El Mansari has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Pierre Blier

    Department of Psychiatry, University of Ottawa Institute of Mental Health Research at The Royal , Ottawa

    12 shared publications
  • Stephen Daniels

    University of Ottawa Institute of Mental Health Research, 1145 Carling Avenue, K1Z 7K4, Ottawa, Canada

    3 shared publications
  • Chidiebere M Iro

    Mood Disorders Research Unit, University of Ottawa Institute of Mental Health Research, Ottawa, Ontario, Canada

    2 shared publications
  • Franck Chenu

    University of Ottawa Institute of Mental Health Research, Ottawa, ON, Canada

    2 shared publications
  • Pierre Blier

    University of Ottawa Institute of Mental Health Research, 1145 Carling Avenue, Ottawa, ON, K1Z 7K4, Canada

    2 shared publications
  • Pierre Blier

    University of Ottawa Institute of Mental Health Research at the Royal, ON, Canada

    2 shared publications

Latest Publications

  • Open Access

    Increase of the AMPA-evoked response of pyramidal neurons in the rat medial prefrontal cortex following acute administration of ketamine and S-ketamine, but not R-ketamine

    by Mostafa El Mansari, Naomichi Okamoto, Pierre Blier

    Background: In preclinical studies, an increase in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) to N-methyl-D-aspartate (NMDA) receptor throughput is the predominant hypothesis posited to explain the rapid antidepressant effect of ketamine and S-ketamine. Several lines of evidence show that this AMPA increase takes place in the medial prefrontal cortex (mPFC), which activation has been shown to induce antidepressant-like effects. The present electrophysiological study was aimed at investigating whether a single dose of drugs with antidepressant-like effects that act on glutamate receptors as a primary target induce an increase of evoked AMPA-induced response of pyramidal neurons in the mPFC. Methods: Microiontophoretic applications of AMPA and NMDA were carried out in male anesthetized rats, following acute administration racemic ketamine, S-ketamine, R-ketamine, and ifenprodil to first assess their effects on their evoked response of mPFC pyramidal neurons. In a second series of experiments, the effects of these drugs were also assessed on the spontaneous firing activity of these neurons. Results: An increase in the AMPA-, but not NMDA-evoked response was observed following a single acute injection of ketamine and S-ketamine, when compared to saline treated rats. However, R-ketamine and the NMDA receptor GluN2B subunit antagonist ifenprodil had no effect on AMPA- and NMDA-induced responses of mPFC pyramidal neurons. The spontaneous firing activity of pyramidal neurons was enhanced by S-ketamine and ifenprodil. Conclusion: An increase in the AMPA-induced response appears to constitute a common factor underlying the antidepressant-like effects of ketamine and S-ketamine. This increase did not correlate with change in mPFC pyramidal neurons firing activity. Significance statement An increase in AMPA receptors throughput has emerged as common effect in response to drugs aiming at glutamate receptors as a primary target. This study investigated the effects of 4 such drugs on AMPA- and NMDA-evoked responses and the spontaneous firing activity of pyramidal neurons in medial prefrontal cortex. While racemic ketamine and its enantiomer S-ketamine augmented the AMPA-evoked responses, R-ketamine and ifenprodil did not. Evoked NMDA responses were not altered by these drugs. Only S-ketamine and ifenprodil increased the spontaneous firing activity of pyramidal neurons. Thus, only S-ketamine administration resulted in a simultaneous increase in AMPA response and pyramidal neurons firing activity. An increase in AMPA responsiveness in the rat mPFC correlates with the clinical antidepressant effect of racemic ketamine and S-ketamine.


  • Open Access

    α 5 -GABA A allosteric modulation triggers and prolongs dopamine neuronal activity via AMPA receptors

    by Areebah Ahmed, Mostafa El Mansari, Pierre Blier

    Background: Negative allosteric modulators (NAMs) of gamma-aminobutyric acid (GABA A ) receptors targeting the α 5 -subunit, primarily expressed on glutamate pyramidal neurons in the hippocampus and cortex, reduce inhibitory tone and enhance α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor throughput. The α 5 -GABA A -NAM, L-655,708, has shown rapid and sustained antidepressant-like effects in rodents. Aim: This study aimed to investigate the effects of L-655,708 on the monoamine and glutamate systems in rats in relation to the antidepressant-like response. Methods: Male Sprague-Dawley rats received a single dose of L-655,708 (3 mg/kg, i.p.) or vehicle. In vivo extracellular recordings were conducted in the dorsal raphe nucleus (DRN), locus coeruleus (LC), ventral tegmental area (VTA), and medial prefrontal cortex (mPFC) acutely, 1 day, 1 week, and 2 weeks post-injection. AMPA and N-methyl-D-aspartate (NMDA) responsiveness in the hippocampal CA1 region was assessed using microiontophoresis. Results: The NMDA-induced response in the CA1 hippocampus was significantly reduced 1 day post-injection of L655,708, while the AMPA response remained unchanged. Although mPFC pyramidal neurons’ firing was not changed, there was a two-fold increase in population activity of VTA dopamine (DA) neurons 1 day post-injection, lasting up to 1 week. Flumazenil, the benzodiazepine site antagonist, and 2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX), an AMPA receptor antagonist, blocked this effect. L-655,708 had no acute effect on firing activity of serotonin or norepinephrine neurons. Conclusion: L-655,708 enhanced VTA DA neuron population activity for up to 1 week after a single injection. This effect was dependent on AMPA and took place through action on the benzodiazepine site.

  • Open Access

    AMPA receptors modulate enhanced dopamine neuronal activity induced by the combined administration of venlafaxine and brexpiprazole

    by Stephen Daniels, Mostafa El Mansari, Pierre Blier

    Addition of dopamine (DA)/serotonin (5-HT) partial agonists to 5-HT/norepinephrine (NE) reuptake inhibitors are commonly used to enhance the antidepressant response. The simultaneous inhibition of 5-HT and NE transporters with venlafaxine and its combination of brexpiprazole, which blocks the α2-adrenergic autoreceptor on NE terminals, could constitute a superior strategy. Anesthetized rats received venlafaxine and brexpiprazole for 2 and 14 days, then the firing activity of dorsal raphe nucleus 5-HT, locus coeruleus NE, and ventral tegmental area DA neurons were assessed. Net 5-HT and NE neurotransmissions were evaluated by assessing the tonic activation of 5-HT1A, and α1- and α2-adrenergic receptors in the hippocampus. The combination of brexpiprazole with venlafaxine resulted in normalized 5-HT and NE neuron activity, which occurred earlier than that with venlafaxine alone. A significant enhancement of the tonic activation of 5-HT1A receptors and α2-adrenoceptors in the hippocampus was observed following administration of the combination for 14 days. The combination more than doubled the number of DA neurons per electrode descent, after both 2 and 14 days, while this increase was observed only after 14 days of venlafaxine administration. This increase in population activity was prevented by NBQX, an AMPA receptor antagonist. In conclusion, early during administration, the combination of venlafaxine with brexpiprazole normalized firing activity of 5-HT and NE neurons, and increased the population activity of DA neurons through AMPA receptors. In the hippocampus, there was an overall increase in both 5-HT and NE transmissions. These results imply that this strategy could be a rapid-acting approach to treat depression.


  • Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α2-adrenoceptor sensitivity

    by Mostafa El Mansari, Rami Hamoudeh, Stephen Daniels, Pierre Blier

    Background: Wistar Kyoto (WKY) rats manifest abnormalities in the function of monoamine receptors and transporters, as well as levels of these neurotransmitters in the brain. The present study assessed alterations in the firing activity of serotonin (5-hydroxytryptamine [5-HT]), norepinephrine (NE), and dopamine (DA) neurons, as well as the activity of 5-HT and NE receptors and transporters in the hippocampus. Methods: In vivo electrophysiological recordings were conducted in male WKY and Wistar rats. Extracellular single-unit recordings of 5-HT, NE, and DA neurons were performed. Recordings of pyramidal neurons were conducted in the medial prefrontal cortex (mPFC) and the hippocampus, where direct application of 5-HT and NE by iontophoresis was also carried out. Results: The mean firing rate of 5-HT neurons was significantly decreased in WKY compared to Wistar rats. The burst activity of NE neurons was significantly increased in WKY, while their mean firing activity was not changed. There was no alteration in the firing, burst, and population activity of DA neurons in WKY animals. In the hippocampus, a decrease in sensitivity of α2-adrenoceptors, but not 5-HT receptors, was observed. There was, however, no change in the activity of 5-HT and NE transporters. The firing activity of mPFC pyramidal neurons was similar in WKY versus Wistar rats. Conclusion: In WKY rats, there was a decrease in the firing activity of 5-HT neurons. There was also an enhanced burst activity of NE neurons, accompanied by a reduction in sensitivity of the α2-adrenoceptor in the hippocampus, inferring a decrease in NE transmission.


  • Open Access

    Ketamine promptly normalizes excess norepinephrine and enhances dopamine neuronal activity in Wistar Kyoto rats

    by Stephen Daniels, Mostafa El Mansari, Rami Hamoudeh, Pierre Blier

    Ketamine acts primarily by blocking the N-methyl-D-aspartate (NMDA) receptor at the phencyclidine site. The rapid antidepressant properties of ketamine were demonstrated in the clinic and several behavioral models of depression in rodents. We hypothesized that the normalization of abnormal activity of monoamine neurons in Wistar Kyoto (WKY) rats contributes to the rapid antidepressant effects of ketamine. A single administration of ketamine (10 mg/kg, i. p) or saline was administered to anesthetized WKY rats beforein vivoelectrophysiological recordings of dorsal raphe nucleus (DRN) serotonin (5-HT), locus coeruleus (LC) norepinephrine (NE) and ventral tegmental area (VTA) dopamine (DA) neuronal activity. Pyramidal neurons from the medial prefrontal cortex (mPFC) were also recorded before and after a ketamine injection. In the VTA, ketamine elicited a significant increase in the population activity of DA neurons. This enhancement was consistent with findings in other depression-like models in which such a decreased population activity was observed. In the LC, ketamine normalized increased NE neuron burst activity found in WKY rats. In the DRN, ketamine did not significantly reverse 5-HT neuronal activity in WKY rats, which is dampened compared to Wistar rats. Ketamine did not significantly alter the neuronal activity of mPFC pyramidal neurons. These findings demonstrate that ketamine normalized NE neuronal activity and enhanced DA neuronal activity in WKY rats, which may contribute to its rapid antidepressant effect.


  • Open Access

    Corrigendum to: Repeated but not Single Administration of Ketamine Prolongs Increases of the Firing Activity of Norepinephrine and Dopamine Neurons

    by Chidiebere M Iro, Rami Hamati, Mostafa El Mansari, Pierre Blier

    Iro, C.M., Hamati, R., Mansari, M. E., and Blier, P. (2021) Repeated but not Single Administration of Ketamine Prolongs Increases of the Firing Activity of Norepinephrine and Dopamine Neurons. International Journal of Neuropsychopharmacology.

  • Open Access

    Repeated but Not Single Administration of Ketamine Prolongs Increases of the Firing Activity of Norepinephrine and Dopamine Neurons

    by Chidiebere M Iro, Rami Hamati, Mostafa El Mansari, Pierre Blier

    Background: Clinical studies have shown that the rapid antidepressant effect of the glutamate N-methyl-D-aspartate receptor antagonist ketamine generally disappears within 1 week but can be maintained by repeated administration. Preclinical studies showed that a single ketamine injection immediately increases the firing and burst activity of norepinephrine (NE) neurons, but not that of serotonin (5-HT) neurons. It also enhances the population activity of dopamine (DA) neurons. In the present study, we investigated whether such alterations of monoamine neuronal firing are still present 1 day after a single injection, and whether they can be maintained by repeated injections. Methods: Rats received a single ketamine injection or 6 over 2 weeks and the firing activity of dorsal raphe nucleus 5-HT, locus coeruleus NE, and ventral tegmental area DA neurons was assessed. Results: One day following a single injection of ketamine, there was no change in the firing activity of 5-HT, NE, or DA neurons. One day after repeated ketamine administration, however, there was a robust increase of the firing activity of NE neurons and an enhancement of burst and population activities of DA neurons, but still no change in firing parameters of 5-HT neurons. The increased activity of NE neurons was no longer present 3 days after the last injection, whereas that of DA neurons was still present. DA neurons were firing normally 7 days after repeated injections. Conclusion: These results imply that the enhanced activity of NE and DA neurons may play a significant role in the maintenance of the antidepressant action of ketamine.


  • Open Access

    Involvement of 5-HT1A and 5-HT2A Receptors but Not α2-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo

    by Anna Herman, Mostafa El Mansari, Nika Adham, Béla Kiss, Bence Farkas, Pierre Blier

    Cariprazine, an orally active and potent dopamine D3–preferring D3/D2 receptor partial agonist, is approved to treat adults with schizophrenia (in the United States and Europe) and manic or mixed episodes associated with bipolar I disorder (in the United States). Cariprazine also displays partial agonism at serotonin [5-hydroxytryptamine (5-HT)] 5-HT1A receptors and antagonism at 5-HT2A and 5-HT2B receptors in vitro. The study objective was to determine whether cariprazine leads to functional alterations of monoamine systems in vivo via electrophysiological recordings from anesthetized rats. Dorsal raphe nucleus (DRN), locus coeruleus (LC), and hippocampus pyramidal neurons were recorded, and cariprazine was administered systemically or locally through iontophoresis. In the DRN, cariprazine completely inhibited the firing activity of 5-HT neurons, which was fully reversed by the 5-HT1A receptor antagonist, WAY100635. In the LC, cariprazine reversed the inhibitory effect of the preferential 5-HT2A receptor agonist, 2,5-dimethoxy-4-iodoamphetamine, on norepinephrine (NE) neurons (ED50 = 66 µg/kg) but did not block the inhibitory effect of the α2-adrenergic receptor agonist, clonidine. Cariprazine, iontophorized into the hippocampus, diminished pyramidal neuronal firing through activation of 5-HT1A receptors, while its concomitant administration did not dampen the suppressant effect of 5-HT. These results indicate that, in vivo, cariprazine acted as a 5-HT1A autoreceptor agonist in the DRN, a 5-HT2A receptor antagonist in modulating the firing activity of LC NE neurons, and a full agonist at 5-HT1A receptors mediating the electrophysiological effect of 5-HT on pyramidal neurons. The modulatory actions of cariprazine on these monoaminergic systems may contribute to its therapeutic effectiveness in patients with depressive episodes.